Company Name
Canaan Research & Investment, s.l.

Activity
Biotech Holding focused on different health areas: diagnosis, neurological diseases, nutraceuticals and dermatology.

CIF
B87162335

Sector
Biotechnology

Address
Avda. Industria, nº 4, edificio 1, planta baja, local D (Natea Business Park) - ALCOBENDAS (Madrid)

EPM Joining Date
22/09/2021

Creation Date
03/12/2014

Founders Tres socios fundadores: Enrique Sainz Martínez, Juan José Montoya Miñano, Alfonso Ortega Gallego. Actualmente, además de los 3 socios fundadores, la empresa cuenta con 12 accionistas más en Canaan. Cada una de las empresas participadas por Canaan en más del 50% tiene además sus propios accionistas

Investors email contact
esainz@canaanrd,com

Presenting Partner
EpM

Company profile

Biotech Holding focused on molecular diagnosis, CNS pathologies, dermatology & nutraceutical areas, with a focus on projects of high innovative intensity from research centers, universities and public foundations for their development and traslationality to the current market.

Science to Market

Enrique Sainz Martínez
CEO

On the Road to BME Growth

Relevant data

(thousand of Euros)20192020
Net worth310310
Net business turnover252278
Financial debt31427
Ebitda3541
Net Profit1734
Average number of employees1515

 

Investment Rounds

Date Status Amount Minimum Ticket
04-10-2021Open1.500.00010000,00

 

Business Model

Development of biotechnological projects with high potential (and from public research centers and institutions, universities and foundations), for through a business structure, to obtain, validate and commercialize new biotechnological products that meet unmet needs in the Biotech Industry and improve people's quality of life.

Competitive advantage

CANAAN uses the Open Innovation model through which the company cooperates and works with its external environment through partnerships with research centers and public institutions, taking advantage of the knowledge generated in these centers, with the aim of generating all the subsequent development that transform this knowledge and R&D towards highly innovative products and licenses that can be transferred to the market.

The Open Innovation model has as main advantages:

- Cost reduction and optimization.
- Maximization of technology transfer with research centers and companies.
- Talent attraction.

Scalability

Having in our portfolio marketable technologies and products in some cases in the market or in advanced stage of development allows us to ensure scalability both at the territorial level, since the target objective of our companies is obviously international, and in terms of the scope of the sector in which Canaan operates, the health sector is an area of maximum impact with a continuous market growth.

Contact Us

You are just one step away from growing your company